Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:DLEU1-STIM1

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: DLEU1-STIM1
	FusionPDB ID: 23004
	FusionGDB2.0 ID: 23004
		Hgene	Tgene
	Gene symbol	DLEU1	STIM1
	Gene ID	10301	6786
	Gene name	deleted in lymphocytic leukemia 1	stromal interaction molecule 1
	Synonyms	BCMS\|BCMS1\|DLB1\|DLEU2\|LEU1\|LEU2\|LINC00021\|NCRNA00021\|XTP6	D11S4896E\|GOK\|IMD10\|STRMK\|TAM\|TAM1
	Cytomap	13q14.2-q14.3	11p15.4
	Type of gene	ncRNA	protein-coding
	Description	B-cell neoplasia-associated gene with multiple splicingdeleted in lymphocytic leukemia 1 (non-protein coding)leukemia-associated protein 2long intergenic non-protein coding RNA 21	stromal interaction molecule 1
	Modification date	20200313	20200329
	UniProtAcc	O43261 Main function of 5'-partner protein: FUNCTION: May act as a tumor suppressor.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000490577, ENST00000378180,	ENST00000300737, ENST00000527651, ENST00000527484, ENST00000533977,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	14 X 13 X 4=728	11 X 11 X 4=484
	# samples	14	12
	** MAII score	log2(14/728*10)=-2.37851162325373 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(12/484*10)=-2.01197264166608 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: DLEU1 [Title/Abstract] AND STIM1 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: DLEU1 [Title/Abstract] AND STIM1 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	DLEU1(50656693)-STIM1(4076753), # samples:1
Anticipated loss of major functional domain due to fusion event.	DLEU1-STIM1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. DLEU1-STIM1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. DLEU1-STIM1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. DLEU1-STIM1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	STIM1	GO:0002115	store-operated calcium entry	28219928
Tgene	STIM1	GO:0005513	detection of calcium ion	16005298
Tgene	STIM1	GO:0032237	activation of store-operated calcium channel activity	16005298\|26322679\|28219928
Tgene	STIM1	GO:0045762	positive regulation of adenylate cyclase activity	19171672
Tgene	STIM1	GO:0051924	regulation of calcium ion transport	16005298

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:50656693/chr11:4076753)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across DLEU1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across STIM1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000378180

DLEU1

chr13

50656693

ENST00000300737

STIM1

chr11

4076753

3471

387

266

2059

597

ENST00000378180

DLEU1

chr13

50656693

ENST00000527651

STIM1

chr11

4076753

2097

387

266

1624

452

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000378180	ENST00000300737	DLEU1	chr13	50656693	+	STIM1	chr11	4076753	+	0.006807338	0.99319273
ENST00000378180	ENST00000527651	DLEU1	chr13	50656693	+	STIM1	chr11	4076753	+	0.01851791	0.98148215

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for DLEU1-STIM1

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
DLEU1	chr13	50656693	STIM1	chr11	4076753	387	40	QGLSHLSLGTTLPVYNWTVDEVVQWL

Top

Potential FusionNeoAntigen Information of DLEU1-STIM1 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

DLEU1-STIM1_50656693_4076753.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:01	TTLPVYNW	0.9997	0.9943	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:02	TTLPVYNW	0.9991	0.984	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:01	LPVYNWTV	0.999	0.6765	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:01	TTLPVYNW	0.9986	0.9822	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:03	TTLPVYNW	0.9976	0.9967	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:02	LPVYNWTV	0.9973	0.635	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:01	GTTLPVYNW	0.9979	0.9778	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:01	GTTLPVYNW	0.9958	0.9893	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:01	SLGTTLPVY	0.9926	0.8706	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:02	GTTLPVYNW	0.9895	0.9729	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:22	TLPVYNWTV	0.9827	0.9149	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:17	GTTLPVYNW	0.9782	0.9601	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:38	TLPVYNWTV	0.9721	0.8061	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:11	TLPVYNWTV	0.9714	0.8889	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:21	TLPVYNWTV	0.9709	0.9271	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:27	TLPVYNWTV	0.9689	0.842	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:60	TLPVYNWTV	0.968	0.8842	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:24	TLPVYNWTV	0.9678	0.8791	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:30	TLPVYNWTV	0.9678	0.8791	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:67	TLPVYNWTV	0.9678	0.8791	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:35	TLPVYNWTV	0.967	0.9019	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:29	TLPVYNWTV	0.9605	0.8752	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:13	TLPVYNWTV	0.9594	0.8723	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:20	TLPVYNWTV	0.9553	0.8821	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:16	TLPVYNWTV	0.9503	0.8469	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:25	SLGTTLPVY	0.9415	0.9208	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:19	TLPVYNWTV	0.9407	0.7711	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:16	GTTLPVYNW	0.9391	0.9505	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:04	TLPVYNWTV	0.9277	0.9572	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:03	GTTLPVYNW	0.9222	0.9936	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A32:13	GTTLPVYNW	0.9065	0.9442	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:02	SLGTTLPVY	0.9011	0.9321	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:17	TLPVYNWTV	0.8786	0.7537	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:01	LGTTLPVYNW	0.9998	0.9921	7	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:01	LGTTLPVYNW	0.9988	0.981	7	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:17	LSLGTTLPVY	0.9961	0.9411	5	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:03	LGTTLPVYNW	0.993	0.9951	7	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:16	LSLGTTLPVY	0.9752	0.8664	5	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:01	SLGTTLPVYNW	0.9982	0.9916	6	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:02	HLSLGTTLPVY	0.9799	0.8893	4	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:08	LPVYNWTV	0.9958	0.5387	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:05	TLPVYNWTV	0.9844	0.7825	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:02	TLPVYNWTV	0.9825	0.7418	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:01	TLPVYNWTV	0.9678	0.8791	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:07	TLPVYNWTV	0.966	0.9056	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:07	SLGTTLPVY	0.9466	0.6594	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:21	SLGTTLPVY	0.8984	0.899	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:05	SLGTTLPVY	0.7438	0.8302	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:04	SLGTTLPVY	0.7139	0.8708	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:31	SLGTTLPVY	0.6666	0.8437	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-C01:30	TLPVYNWTV	0.1152	0.986	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-C01:17	TLPVYNWTV	0.078	0.9834	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:10	TTLPVYNW	0.9997	0.9943	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:04	TTLPVYNW	0.9993	0.7758	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B78:02	LPVYNWTV	0.9991	0.8511	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:13	LPVYNWTV	0.999	0.5296	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:14	LPVYNWTV	0.999	0.5998	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:06	TTLPVYNW	0.9988	0.9571	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:21	LPVYNWTV	0.9978	0.6611	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:09	LPVYNWTV	0.9977	0.6456	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:02	TTLPVYNW	0.9975	0.9393	9	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:29	LPVYNWTV	0.9873	0.5129	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B51:05	LPVYNWTV	0.9849	0.6531	11	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:10	GTTLPVYNW	0.9958	0.9893	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:04	GTTLPVYNW	0.995	0.8359	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:27	SLGTTLPVY	0.9928	0.9015	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:33	SLGTTLPVY	0.9926	0.8706	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:34	SLGTTLPVY	0.9926	0.8706	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:125	SLGTTLPVY	0.9926	0.8706	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:50	SLGTTLPVY	0.9921	0.9193	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:135	SLGTTLPVY	0.991	0.8846	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:12	SLGTTLPVY	0.9868	0.8796	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:02	GTTLPVYNW	0.9831	0.9758	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A32:01	GTTLPVYNW	0.9764	0.9574	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B58:06	GTTLPVYNW	0.9738	0.9395	8	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:14	TLPVYNWTV	0.9722	0.9051	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A02:06	TLPVYNWTV	0.9709	0.9271	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:35	SLGTTLPVY	0.9615	0.8783	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:39	SLGTTLPVY	0.9397	0.8579	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B15:20	SLGTTLPVY	0.7677	0.8925	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B35:28	SLGTTLPVY	0.6619	0.8941	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B35:20	SLGTTLPVY	0.6435	0.9025	6	15
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-C01:03	TLPVYNWTV	0.1073	0.9789	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-C01:02	TLPVYNWTV	0.077	0.983	10	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:10	LGTTLPVYNW	0.9998	0.9921	7	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:04	LGTTLPVYNW	0.9989	0.8056	7	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A68:02	TTLPVYNWTV	0.9826	0.895	9	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-A69:01	TTLPVYNWTV	0.9793	0.9487	9	19
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:04	SLGTTLPVYNW	0.9983	0.8843	6	17
DLEU1-STIM1	chr13	50656693	chr11	4076753	387	HLA-B57:10	SLGTTLPVYNW	0.9982	0.9916	6	17

Top

Potential FusionNeoAntigen Information of DLEU1-STIM1 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of DLEU1-STIM1

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
8747	SLGTTLPVYNWTVD	DLEU1	STIM1	chr13	50656693	chr11	4076753	387

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of DLEU1-STIM1

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	8747	SLGTTLPVYNWTVD	-7.15543	-7.26883
HLA-B14:02	3BVN	8747	SLGTTLPVYNWTVD	-4.77435	-5.80965
HLA-B52:01	3W39	8747	SLGTTLPVYNWTVD	-6.80875	-6.92215
HLA-B52:01	3W39	8747	SLGTTLPVYNWTVD	-4.20386	-5.23916
HLA-A11:01	4UQ2	8747	SLGTTLPVYNWTVD	-7.5194	-8.5547
HLA-A11:01	4UQ2	8747	SLGTTLPVYNWTVD	-6.9601	-7.0735
HLA-A24:02	5HGA	8747	SLGTTLPVYNWTVD	-7.52403	-7.63743
HLA-A24:02	5HGA	8747	SLGTTLPVYNWTVD	-5.82433	-6.85963
HLA-B27:05	6PYJ	8747	SLGTTLPVYNWTVD	-3.28285	-4.31815
HLA-B44:05	3DX8	8747	SLGTTLPVYNWTVD	-5.91172	-6.94702
HLA-B44:05	3DX8	8747	SLGTTLPVYNWTVD	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of DLEU1-STIM1

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
DLEU1-STIM1	chr13	50656693	chr11	4076753	10	19	TLPVYNWTV	CTTTACCAGTATACAATTGGACCGTGG
DLEU1-STIM1	chr13	50656693	chr11	4076753	11	19	LPVYNWTV	TACCAGTATACAATTGGACCGTGG
DLEU1-STIM1	chr13	50656693	chr11	4076753	4	15	HLSLGTTLPVY	ACTTAAGCCTCGGAACAACTTTACCAGTATACA
DLEU1-STIM1	chr13	50656693	chr11	4076753	5	15	LSLGTTLPVY	TAAGCCTCGGAACAACTTTACCAGTATACA
DLEU1-STIM1	chr13	50656693	chr11	4076753	6	15	SLGTTLPVY	GCCTCGGAACAACTTTACCAGTATACA
DLEU1-STIM1	chr13	50656693	chr11	4076753	6	17	SLGTTLPVYNW	GCCTCGGAACAACTTTACCAGTATACAATTGGA
DLEU1-STIM1	chr13	50656693	chr11	4076753	7	17	LGTTLPVYNW	TCGGAACAACTTTACCAGTATACAATTGGA
DLEU1-STIM1	chr13	50656693	chr11	4076753	8	17	GTTLPVYNW	GAACAACTTTACCAGTATACAATTGGA
DLEU1-STIM1	chr13	50656693	chr11	4076753	9	17	TTLPVYNW	CAACTTTACCAGTATACAATTGGA
DLEU1-STIM1	chr13	50656693	chr11	4076753	9	19	TTLPVYNWTV	CAACTTTACCAGTATACAATTGGACCGTGG

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of DLEU1-STIM1

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
N/A	DLEU1-STIM1	chr13	50656693	ENST00000378180	chr11	4076753	ENST00000300737	DB149054

Top

Potential target of CAR-T therapy development for DLEU1-STIM1

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

STIM1

chr13:50656693

chr11:4076753

ENST00000300737

214_234

686.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to DLEU1-STIM1

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to DLEU1-STIM1

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)